A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants With Advanced/Metastatic Solid Tumors
Merck Sharp & Dohme LLC
Summary
Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and/or advanced (metastatic) solid tumors: * Colorectal carcinoma (CRC) * Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and/or rhabdoid features) * Nonsquamous non-small cell lung cancer (NSCLC) * Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC) * Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) * Has adequate organ functi…
Interventions
- DrugMK-4884
Oral Administration
Locations (4)
- NEXT Oncology ( Site 0151)San Antonio, Texas
- Rambam Health Care Campus ( Site 0051)Haifa
- Rabin Medical Center ( Site 0053)Petah Tikva
- National Cancer Center Hospital ( Site 0201)Chūō, Tokyo